Rigel Pharmaceuticals reported $214.93M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.36B 598M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Celldex Therapeutics USD 663.74M 61.2M Sep/2026
Daiichi Sankyo JPY 2.38T 150.33B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Veracyte USD 467.88M 106.9M Sep/2026